Key facts
- It has raised $540K across 1 recorded rounds; the latest was Seed Round ($540K) in Jan 2025.
- Neuro-Innovators has filed 2 Form Ds with the SEC since 2023, most recently Feb 2025 ($540K sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Neuro-Innovators
Funding rounds
1 roundsAbout Neuro-Innovators
Developer of neuroplastic medicine drugs intended to accelerate brain neuroplasticity for patients suffering from brain injuries and diseases. The company specializes in neuroplastic medicine for patients suffering from chronic motor deficits from stroke, including dementia and brain disorders, depression, and neuropsychiatric disorders, to make rehabilitation protocols clinically and functionally effective through multiple pathways, enabling patients with the environment for brain recovery.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2021
- Employees
- 9
- Website
- neuro-innovators.com/
- Ownership
- Privately Held (backing)
Neuro-Innovators doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuro-Innovators shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuro-Innovators in its N-PORT filings yet. We sweep new filings monthly.